Overall survival following heterogeneous FDG-guided dose-escalation for locally advanced NSCLC in the international phase III NARLAL2 trial.

Schytte, T., Kristiansen, C., Khalil, A. et al. (17 more authors) (2024) Overall survival following heterogeneous FDG-guided dose-escalation for locally advanced NSCLC in the international phase III NARLAL2 trial. Journal of Clinical Oncology, 42 (17_suppl). ISSN 0732-183X

Metadata

Item Type: Article
Authors/Creators:
  • Schytte, T.
  • Kristiansen, C.
  • Khalil, A.
  • Hansen, O.
  • Land, L.H.
  • Brink, C.
  • Nielsen, T.
  • Nielsen, M.
  • Hansen, T.S.
  • Poehl, M.
  • Persson, G.
  • Haakensen, V.
  • Halvorsen, T.O.
  • Sundby, F.
  • Schmidt, H.
  • Hoffmann, L.
  • Appelt, A.L. ORCID logo https://orcid.org/0000-0003-2792-9218
  • Møller, D.S.
  • Lutz, C.
  • Knap, M.
Copyright, Publisher and Additional Information:

This is an author produced version of a conference paper accepted for publication in Journal of Clinical Oncology. Uploaded in accordance with the publisher's self-archiving policy.
Dates:
  • Published: 10 June 2024
  • Published (online): 5 June 2024
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Leeds Institute of Medical Research (LIMR) > Division of Oncology
Depositing User: Symplectic Publications
Date Deposited: 28 Jun 2024 13:30
Last Modified: 28 Jun 2024 13:30
Status: Published
Publisher: American Society of Clinical Oncology
Identification Number: 10.1200/jco.2024.42.17_suppl.lba8069
Open Archives Initiative ID (OAI ID):

Download

Accepted Version


Embargoed until: 5 June 2025

Filename: NARLAL2 ASCO abstract - Overall survival following heterogeneous FDG.pdf

Request a copy

file not available

Export

Statistics


CORE (COnnecting REpositories)